Cyclacel Pharmaceuticals Inc (CYCC) — Strategic Asset Allocation Index
Cyclacel Pharmaceuticals Inc (CYCC) has a Strategic Asset Allocation Index of 1.5% as of June 2023. Strategic assets (PP&E of $148.00K plus long-term investments of $-) total $148.00K, measured against net assets of $9.63 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check how resilient are Cyclacel Pharmaceuticals Inc's assets to evaluate the company's liquid asset resilience ratio.
SAAI
Strategic Assets
PP&E
Net Assets
Cyclacel Pharmaceuticals Inc Strategic Asset Allocation Index (2006–2022)
This chart shows how Cyclacel Pharmaceuticals Inc's Strategic Asset Allocation Index has evolved across 17 annual periods from 2006 to 2022. As of June 2023, the index stands at 1.5%, representing strategic assets of $148.00K against net assets of $9.63 Million USD. See Cyclacel Pharmaceuticals Inc (CYCC) flexibility index to measure the company's free cash flow as a share of total liabilities.
Annual Strategic Asset Allocation Index for Cyclacel Pharmaceuticals Inc (2006–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Cyclacel Pharmaceuticals Inc from 2006 to 2022, covering 17 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see Cyclacel Pharmaceuticals Inc (CYCC) total market value.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 0.9% | $174.00K | $174.00K | $- | $20.43 Million | ▲ +0.6 pp |
| 2021 | 0.2% | $94.00K | $94.00K | $- | $37.69 Million | ▼ -0.1 pp |
| 2020 | 0.3% | $106.00K | $106.00K | $- | $33.26 Million | ▲ +0.1 pp |
| 2019 | 0.2% | $27.00K | $27.00K | $- | $11.70 Million | ▼ 0.0 pp |
| 2018 | 0.2% | $36.00K | $36.00K | $- | $15.27 Million | ▲ +0.1 pp |
| 2017 | 0.1% | $29.00K | $29.00K | $- | $21.77 Million | ▼ -0.2 pp |
| 2016 | 0.3% | $45.00K | $45.00K | $- | $14.27 Million | ▼ -0.7 pp |
| 2015 | 1.1% | $198.00K | $198.00K | $- | $18.84 Million | ▼ -0.7 pp |
| 2014 | 1.8% | $387.00K | $387.00K | $- | $21.69 Million | ▲ +0.8 pp |
| 2013 | 1.0% | $275.00K | $275.00K | $- | $28.02 Million | ▼ -0.3 pp |
| 2012 | 1.3% | $129.00K | $129.00K | $- | $10.02 Million | ▲ +0.4 pp |
| 2011 | 0.9% | $167.00K | $167.00K | $- | $19.50 Million | ▼ -0.8 pp |
| 2010 | 1.6% | $408.00K | $408.00K | $- | $24.92 Million | ▼ -17.8 pp |
| 2009 | 19.4% | $901.00K | $901.00K | $- | $4.64 Million | ▲ +10.9 pp |
| 2008 | 8.5% | $1.75 Million | $1.75 Million | $- | $20.64 Million | ▲ +3.3 pp |
| 2007 | 5.2% | $3.02 Million | $3.02 Million | $- | $57.97 Million | ▲ +1.3 pp |
| 2006 | 3.9% | $2.12 Million | $2.12 Million | $- | $53.92 Million | — |